TIDMCOG

Cambridge Cognition Holdings PLC

16 March 2017

Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

CANTAB(R) assessments used in EBBINGHAUS cognitive function trial for Amgen's evolocumab

16 March 2017: The neuroscience digital health company Cambridge Cognition Holdings PLC (Cambridge, UK - LSE: COG), which develops and markets software products to improve brain health, today reports its involvement in Amgen's EBBINGHAUS study with full results being presented at the American College of Cardiology Annual Scientific Session on 18 March 2017.

The EBBINGHAUS researchers used Cambridge Cognition's CANTAB(R) digital cognitive assessments, an industry standard for cognitive outcomes measurement. CANTAB products are designed to improve data quality and operational efficiencies in large multinational clinical trials such as this.

Amgen recently announced positive results of the FOURIER and EBBINGHAUS trials evaluating the human anti-PCSK9 monoclonal antibody evolocumab (Repatha(R) ). The EBBINGHAUS trial is the first of its kind to prospectively explore the relationship between very low LDL cholesterol levels and neurocognitive function(*) .

The FOURIER trial conducted in 27,564 patients with clinically evident atherosclerotic cardiovascular disease (ASCVD) found evolocumab reduced the risk of cardiovascular events, by reducing high levels of LDL cholesterol. The EBBINGHAUS cognitive function trial conducted in a subset of 1,974 FOURIER patients also achieved its primary endpoint, demonstrating that evolocumab was non-inferior to placebo for the effect on cognitive function.

Kenton Zavitz PhD, Director of Clinical Affairs, Cambridge Cognition commented: "By all measures EBBINGHAUS is a landmark cognitive study. The study involved 1,974 patients across 30 countries worldwide using our tablet-based CANTAB cognitive technology. Researchers were able to reliably assess study subjects for effects on executive function, memory, and psychomotor speed at baseline and select time points. CANTAB software enabled assessments to be carried out in a patient-friendly manner and ensure consistent and reliable data capture that could be translated into meaningful results, without the need for a specialist in neuropsychology at each trial site."

Full results from the evolocumab EBBINGHAUS cognitive function trial will be presented at the American College of Cardiology (ACC) 66th Annual Scientific Session Late-Breaking Clinical Trials session on Saturday, March 18, 2017 at 9 a.m. ET.

Notes to editors

EBBINGHAUS Study Design

EBBINGHAUS (Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in high cardiovascUlar risk Subjects) is a double-blind, placebo-controlled randomized non-inferiority trial involving 1,974 patients enrolled in the FOURIER outcomes study. The primary endpoint in the study is the Spatial Working Memory strategy index of executive function. Secondary endpoints are working memory, as assessed by the CANTAB Spatial Working Memory (SWM) test between-errors score; memory function, as assessed by the CANTAB Paired Associates Learning (PAL) test; and psychomotor speed, as assessed by the CANTAB Reaction Time (RTI) test.

For further information about this study, you may be interested in reading the following paper:

*Giugliano R.P., et al. (2017) Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial. Clinical Cardiology, 2017.

http://onlinelibrary.wiley.com/doi/10.1002/clc.22678/full

About Cambridge Cognition Holdings PLC

Cambridge Cognition is a neuroscience digital health company developing products and services to better understand, detect and treat conditions affecting brain health. Our cognitive research technologies for mobile, wearable, and online platforms accelerate the research and development of new treatments, enhance research of the brain, and measure cognitive health and wellbeing in patients worldwide.

www.cambridgecognition.com

Enquiries

 
 Cambridge Cognition Holdings PLC 
  Steven Powell, Chief Executive          Tel: 01223 810 
  Officer                                 700 
  Noah Konig, Director of Marketing       press@camcog.com 
  and Communications 
 finnCap Ltd (NOMAD and Joint Broker)   Tel: 020 7220 
  Geoff Nash / Simon Hicks               0500 
  Alice Lane                             (Corporate Finance) 
                                         (Corporate Broking) 
 Dowgate Capital Stockbrokers Limited   Tel: 01293 517 
  (Joint Broker)                         744 
  David Poutney / James Serjeant 
 IFC Advisory Ltd (Financial PR         Tel: 020 3053 
  and IR)                                8671 
  Tim Metcalfe / Graham Herring

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAEAXDSFLPXEFF

(END) Dow Jones Newswires

March 16, 2017 03:01 ET (07:01 GMT)

Cambridge Cognition (LSE:COG)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Cambridge Cognition Charts.
Cambridge Cognition (LSE:COG)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Cambridge Cognition Charts.